• Record December quarter with global sales of US$6.1 million, up 38% on pcp and 25% on the September 2025 quarter
• Global six-month sales of US$10.9 million, up 29% on pcp
• Last Twelve Months (LTM) global sales of ~US$21 million (A$32.2 million), up 24% on prior twelve months and three times higher than the industry growth rate of ~8%

Nova Eye Medical Limited (ASX: EYE) has reported a record sales result for the December 2025 quarter and continued strong growth for the six months ended 31 December 2025. The December quarter result of US$6.1 million reflects continued strong demand in the United States, supported by consistent growth in Rest of World markets. The iTrack technology has now been used in approximately 180,000 surgical cases worldwide. Its minimally invasive, rejuvenative method of action is becoming increasingly recognised by more surgeons as the company's commercial efforts continue. Sales growth in the twelve months to 31 December 2025 was 24% up on the prior year, which is three times the industry growth rate of ~8% estimated by Marketscope. The six months to 31 December 2025 delivered the sixth consecutive half of sales growth since the launch of iTrack Advance in the USA, with a compounded annualised growth rate across this period of ~40%.